SCHEMBL9976810

SCHEMBL9976810

COc1cc2c(cc1OC)-c1c(O)c(OC)cc3c1C(C2)NCC3

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 4/20 0.63
KDM4E B2RXH2 5/20 0.61
ALDH1A1 P00352 5/20 0.61
HPGD P15428 5/20 0.61
HSD17B10 Q99714 4/20 0.61
MAPT P10636 4/20 0.60
KMT2A Q03164 3/20 0.60
LMNA P02545 1/20 0.60
POLB P06746 1/20 0.60
HTT P42858 1/20 0.60
MCL1 Q07820 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
CYP2D6 P10635 3/20 0.59
CYP2C19 P33261 3/20 0.59
TP53 P04637 3/20 0.59
CYP3A4 P08684 3/20 0.59
CASP1 P29466 3/20 0.59
MEN1 O00255 2/20 0.59
CASP7 P55210 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29398835 0.94 ALDH1A1 (0.69) DRD2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL11055620 0.94 ALDH1A1 (0.69) DRD2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL27850407 0.94 ALDH1A1 (0.69) DRD2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL29039792 0.88 DRD2 (0.81) DRD2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL31029778 0.87 KDM4E (0.70) DRD2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL30029891 0.86 HTR2C (0.77) DRD2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL14259791 0.86 DRD1 (0.71) DRD2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL29506718 0.86 HTR2C (0.77) DRD2KDM4EALDH1A1HPGDHSD17B10
SCHEMBL9976807 0.86 DRD1 (0.76) DRD2KDM4EALDH1A1HPGDHSD17B10
Laurotetanine SCHEMBL31300083 0.83 DRD2 (0.74) DRD2KDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8202995-B2 Pharmaceutically acceptable salts of aporphine derivatives and carboxyl group-containing agents and methods for preparing the same STANDARD CHEM. & PHARM. CO., LTD. (TW) 2012-06-19 US disclosed
US-8202995-B2 Pharmaceutically acceptable salts of aporphine derivatives and carboxyl group-containing agents and methods for preparing the same STANDARD CHEM. & PHARM. CO., LTD. (TW) 2012-06-19 US disclosed
US-8093260-B2 Aporphine derivatives and pharmaceutical use thereof STANDARD CHEM. & PHARM. CO., LTD. (TW) 2012-01-10 US disclosed
US-8093260-B2 Aporphine derivatives and pharmaceutical use thereof STANDARD CHEM. & PHARM. CO., LTD. (TW) 2012-01-10 US disclosed
US-20090318489-A1 Aporphine compounds and pharmaceutical use thereof STANDARD CHEM. & PHARM. CO., LTD. (TW) 2009-12-24 US disclosed
US-20090318488-A1 Pharmaceutically acceprable salts of aporphine compounds of carboxyl group-containing agents and methods for preparing the same STANDARD CHEM. & PHARM. CO., LTD. (TW) 2009-12-24 US disclosed
US-20090318488-A1 Pharmaceutically acceprable salts of aporphine compounds of carboxyl group-containing agents and methods for preparing the same STANDARD CHEM. & PHARM. CO., LTD. (TW) 2009-12-24 US disclosed
US-20090318489-A1 Aporphine compounds and pharmaceutical use thereof STANDARD CHEM. & PHARM. CO., LTD. (TW) 2009-12-24 US disclosed
US-7294715-B2 Aporphine and oxoaporphine compounds and pharmaceutical use thereof LOTUS PHARMACEUTICAL CO., LTD. (TW) 2007-11-13 US disclosed
US-7294715-B2 Aporphine and oxoaporphine compounds and pharmaceutical use thereof LOTUS PHARMACEUTICAL CO., LTD. (TW) 2007-11-13 US disclosed
US-4461895-A FOR COMBATTING COLDS AND ALLERGIES WARNER-LAMBERT COMPANY (US) 1984-07-24 US disclosed
EP-0064685-A1 Dibenzo(de,g)quinolines, processes for their preparation and pharmaceutical preparations containing them GÖDECKE AKTIENGESELLSCHAFT (DE) 1982-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318489-A1 Aporphine compounds and pharmaceutical use thereof IAPP, OPRL1, AGER DRD2 163/4885KDM4E 3212/4885ALDH1A1 849/4885
US-20090318488-A1 Pharmaceutically acceprable salts of aporphine compounds of carboxyl group-containing agents and methods for preparing the same IAPP, GPR119, AMY2A DRD2 682/4885KDM4E 3011/4885ALDH1A1 843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.